EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody

Ying Gong, Wilfred T V Germeraad, Xulin Zhang, Nisha Wu, Bo Li, Lynn Janssen, Zongzhong He, Marion J J Gijbels, Bodeng Wu, Birgit L M G Gijsbers, Timo I Olieslagers, Gerard M J Bos und 2 weitere

Molecular Therapy · 2024-08 · 32 (8) · 2711-2727

DOI: 10.1016/j.ymthe.2024.06.034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2024-08. Verfasst von Ying Gong und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Guangdong Engineering and Technology Research Center for Rapid Diagnostic Biosensors, Nanfang Hospital, Southern M…. Hauptthemen laut MEDLINE: Killer Cells, Natural, NK Cell Lectin-Like Receptor Subfamily C, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: H2020 Marie Skłodowska-Curie Actions, 'la Caixa' Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Natural killer (NK) cells eliminate infected or cancer cells via their cytotoxic capacity. NKG2A is an inhibitory receptor on NK cells and cancer cells often overexpress its ligand HLA-E to evade NK cell surveillance. Given the successes of immune checkpoint blockade in cancer therapy, NKG2A is an interesting novel target. However, anti-NKG2A antibodies have shown limited clinical response. In the pursuit of enhancing NK cell-mediated anti-tumor responses, we devised a Cas9-based strategy to delete KLRC1, encoding NKG2A, in human primary NK cells. Our approach involved electroporation of KLRC1-targeting Cas9 ribonucleoprotein resulting in effective ablation of NKG2A expression. Compared with anti-NKG2A antibody blockade, NKG2AKO NK cells exhibited enhanced activation, reduced suppressive signaling, and elevated expression of key transcription factors. NKG2AKO NK cells overcame inhibition from HLA-E, significantly boosting NK cell activity against solid and hematologic cancer cells. We validated this efficacy across multiple cell lines, a xenograft mouse model, and primary human leukemic cells. Combining NKG2A knockout with antibody coating of tumor cells further enhanced cytotoxicity through ADCC. Thus, we provide a comprehensive comparison of inhibition of the NKG2A pathway using genetic ablation and antibodies and provide novel insight in the observed differences in molecular mechanisms, which can be translated to enhance adoptive NK cell immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalNK Cell Lectin-Like Receptor Subfamily CXenograft Model Antitumor AssaysHumansAnimalsMiceCell Line, TumorHLA-E AntigensNeoplasmsAntibodies, MonoclonalCRISPR-Cas SystemsGene DeletionHistocompatibility Antigens Class ICytotoxicity, Immunologic

Stichwörter der Autor:innen

CRISPR-Cas9HLA-ENKG2Aantibody-dependent cellular cytotoxicitycheckpoint inhibitor immunotherapymultiple immunofluorescence stainingnatural killer cellstumor microenvironment

Substanzen

NK Cell Lectin-Like Receptor Subfamily CKLRC1 protein, humanHLA-E AntigensAntibodies, MonoclonalHistocompatibility Antigens Class I

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Guangdong Engineering and Technology Research Center for Rapid Diagnostic Biosensors, Nanfang Hospital, Southern Medical University, Guangzhou 510515, P.R. China; Department of Interna…
  • Department of Internal Medicine, Division of Hematology, Maastricht University Medical Center+, 6227 HX Maastricht, the Netherlands; GROW - Research Institute for Oncology & Reproduction, Maastricht University, 6202 AZ…
  • State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Vision Science, Guangzhou 510000, China.
  • Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing 400038, P.R. China.
  • Department of Laboratory Medicine, Guangdong Engineering and Technology Research Center for Rapid Diagnostic Biosensors, Nanfang Hospital, Southern Medical University, Guangzhou 510515, P.R. China.
  • Department of Transfusion Medicine of General Hospital of Southern Theatre Command, Guangzhou 510515, P.R. China.

Förderung

  • H2020 Marie Skłodowska-Curie Actions
  • 'la Caixa' Foundation
  • National Natural Science Foundation of China
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Cancer Research Foundation
  • National Science Fund for Distinguished Young Scholars
  • European Commission
  • Universiteit Maastricht

Zitieren

APA

Gong, Y., Germeraad, W. T. V., Zhang, X., Wu, N., Li, B., Janssen, L., He, Z., Gijbels, M. J. J., Wu, B., Gijsbers, B. L. M. G., Olieslagers, T. I., Bos, G. M. J., Zheng, L., & Klein Wolterink, R. G. J. (2024). NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody. Molecular Therapy, 32(8), 2711-2727. https://doi.org/10.1016/j.ymthe.2024.06.034

Vancouver

Gong Y, Germeraad WTV, Zhang X, Wu N, Li B, Janssen L, et al. NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody. Molecular Therapy. 2024;32(8):2711-2727. doi:10.1016/j.ymthe.2024.06.034

BibTeX
@article{Gong2024,
  author = {Gong, Ying and Germeraad, Wilfred T V and Zhang, Xulin and Wu, Nisha and Li, Bo and Janssen, Lynn and He, Zongzhong and Gijbels, Marion J J and Wu, Bodeng and Gijsbers, Birgit L M G and Olieslagers, Timo I and Bos, Gerard M J and Zheng, Lei and Klein Wolterink, Roel G J},
  title = {NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody},
  journal = {Molecular Therapy},
  year = {2024},
  volume = {32},
  number = {8},
  pages = {2711--2727},
  doi = {10.1016/j.ymthe.2024.06.034}
}
Kostenlos starten →